Terms: = Bone cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Treatment
124 results:
1. Targeted inhibition of SCF
Wang J; Ferrena A; Zhang R; Singh S; Viscarret V; Al-Harden W; Aldahamsheh O; Borjihan H; Singla A; Yaguare S; Tingling J; Zi X; Lo Y; Gorlick R; Schwartz EL; Zhao H; Yang R; Geller DS; Zheng D; Hoang BH
Oncogene; 2024 Mar; 43(13):962-975. PubMed ID: 38355807
[TBL] [Abstract] [Full Text] [Related]
2. Proteomics and genomics insights on malignant osteosarcoma.
Kathiresan N; Selvaraj C; Pandian S; Subbaraj GK; Alothaim AS; Safi SZ; Kulathaivel L
Adv Protein Chem Struct Biol; 2024; 138():275-300. PubMed ID: 38220428
[TBL] [Abstract] [Full Text] [Related]
3. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
4. Identification of multiple organ metastasis-associated hub mRNA/miRNA signatures in non-small cell lung cancer.
Zu L; He J; Zhou N; Tang Q; Liang M; Xu S
Cell Death Dis; 2023 Dec; 14(12):798. PubMed ID: 38057344
[TBL] [Abstract] [Full Text] [Related]
5. Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK; Yamamichi T; Yustein JT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511127
[TBL] [Abstract] [Full Text] [Related]
6. Cell cycle arrest: A breakthrough in the supportive care of older cancer patients.
Falandry C; List A; Balducci L
J Am Geriatr Soc; 2023 Jul; 71(7):2297-2307. PubMed ID: 37036091
[TBL] [Abstract] [Full Text] [Related]
7. Clinical Targeted Next-Generation Panel Sequencing Reveals
Marinoff AE; Spurr LF; Fong C; Li YY; Forrest SJ; Ward A; Doan D; Corson L; Mauguen A; Pinto N; Maese L; Colace S; Macy ME; Kim A; Sabnis AJ; Applebaum MA; Laetsch TW; Glade-Bender J; Weiser DA; Anderson M; Crompton BD; Meyers P; Zehir A; MacConaill L; Lindeman N; Nowak JA; Ladanyi M; Church AJ; Cherniack AD; Shukla N; Janeway KA
JCO Precis Oncol; 2023 Mar; 7():e2200334. PubMed ID: 36996377
[TBL] [Abstract] [Full Text] [Related]
8. [Mutation characteristics of osteosarcoma: a single center study of 64 cases using next-generation sequencing].
Gao DL; Dong RF; Liu WF; Gong LH; Xu HR; Niu XH; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):370-375. PubMed ID: 36973198
[No Abstract] [Full Text] [Related]
9. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
Balducci L; Falandry C; List A
Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
[TBL] [Abstract] [Full Text] [Related]
10. A Japanese case of castration-resistant prostate cancer with BRCA2 and rb1 co-loss and TP53 mutation: a case report.
Iwasawa T; Kosaka T; Morita S; Mikami S; Nakamura K; Hongo H; Nishihara H; Oya M
BMC Med Genomics; 2022 Jun; 15(1):138. PubMed ID: 35725469
[TBL] [Abstract] [Full Text] [Related]
11. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
12. treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE.
Raj N; Coffman K; Le T; Do RKG; Rafailov J; Choi Y; Chou JF; Capanu M; Dunphy M; Fox JJ; Grewal RK; Reddy RP; Riedl C; Schoder H; Bodei L; Reidy-Lagunes D
Neuroendocrinology; 2022; 112(12):1177-1186. PubMed ID: 35609558
[TBL] [Abstract] [Full Text] [Related]
13. Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review.
Masuda T; Kosaka T; Nakamura K; Hongo H; Yuge K; Nishihara H; Oya M
BMC Med Genomics; 2022 May; 15(1):118. PubMed ID: 35598018
[TBL] [Abstract] [Full Text] [Related]
14. Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway.
Li Y; Yang S; Yang S
Cells; 2022 Apr; 11(8):. PubMed ID: 35456040
[TBL] [Abstract] [Full Text] [Related]
15. Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.
Hsu JY; Seligson ND; Hays JL; Miles WO; Chen JL
JCO Precis Oncol; 2022 Feb; 6():e2100211. PubMed ID: 35108033
[TBL] [Abstract] [Full Text] [Related]
16. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target.
Franceschini N; Gaeta R; Krimpenfort P; Briaire-de Bruijn I; Kruisselbrink AB; Szuhai K; Palubeckaitė I; Cleton-Jansen AM; Bovée JVMG
Lab Invest; 2022 Apr; 102(4):391-400. PubMed ID: 34921235
[TBL] [Abstract] [Full Text] [Related]
17. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
Thysell E; Köhn L; Semenas J; Järemo H; Freyhult E; Lundholm M; Thellenberg Karlsson C; Damber JE; Widmark A; Crnalic S; Josefsson A; Welén K; Nilsson RJA; Bergh A; Wikström P
Mol Oncol; 2022 Feb; 16(4):846-859. PubMed ID: 34889043
[TBL] [Abstract] [Full Text] [Related]
18. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.
Wang D; Bao H
Cancer Chemother Pharmacol; 2022 Jan; 89(1):31-40. PubMed ID: 34655298
[TBL] [Abstract] [Full Text] [Related]
19. Clinical features and imaging manifestations of retinoblastoma with hepatic metastasis.
Gu H; Wang Y; Huang D; Zhang Y; Zhang W; Hu H; Zhang P; Zhou Y; Yi Y; Han S
Pediatr Blood Cancer; 2021 Oct; 68(10):e28959. PubMed ID: 34291868
[TBL] [Abstract] [Full Text] [Related]
20. Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.
Stachyra K; Dudzisz-Śledź M; Bylina E; Szumera-Ciećkiewicz A; Spałek MJ; Bartnik E; Rutkowski P; Czarnecka AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208339
[TBL] [Abstract] [Full Text] [Related]
[Next]
